33 Days
Source:
اقتصاد سكاي نيوز عربية
Source: اقتصاد سكاي نيوز عربية
33 Daysاقتصاد سكاي نيوز عربية
Source: اقتصاد سكاي نيوز عربية
33 DaysReady to play
Ready to play
American biotech companies are increasingly adopting more secretive measures to protect their research from being quickly copied by Chinese firms, which demonstrate an ability to develop competitive drugs rapidly and at lower costs. This has led to reduced disclosure of clinical trial results, hindering funding and intensifying competition. The number of early-stage trials in China has grown fivefold compared to a decade ago, prompting American companies to acquire early Chinese innovations and to focus their efforts on reducing risks associated with information confidentiality.
Notice: This Is an AI-Generated Summary
Comments (0)